An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Open to people ages 18 years and up

• Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
• Currently tolerating treatment in the parent protocol.
• Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
• Have at least stable disease, as determined by the investigator.
• Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

• Has been permanently discontinued from study treatment in the parent study for any reason.
• Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.